info@seagull-health.com
SeagullHealth
search
DatopotamabDeruxtecan-dlnk(Datroway)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Datroway(DatopotamabDeruxtecan-dlnk) Instructions:Uses,Dosage, Side Effects
DATROWAY (datopotamab deruxtecan-dlnk) is a Trop-2-directed antibody-drug conjugate (ADC) that combines a humanized monoclonal antibody with a topoisomerase I inhibitor. The ADC is designed to deliver the cytotoxic agent directly to tumor cells expressing Trop-2, leading to DNA damage and cell death. It is supplied as a lyophilized powder in single-dose vials and is administered via intravenous infusion. This innovative therapy represents a targeted approach for treating advanced breast cancer in specific patient populations.
DATROWAY is indicated for adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (IHC 0, IHC 1+, or IHC 2+/ISH-) who have received prior endocrine-based therapy and chemotherapy in the metastatic or unresectable setting.
Recommended dose: 6 mg/kg (maximum 540 mg for patients ≥90 kg) administered as an intravenous infusion once every 3 weeks.
Premedication with antihistamines, antipyretics, antiemetics, lubricating eye drops, and steroid mouthwash is required.
Infusion duration: 90 minutes for the first infusion, 30 minutes for subsequent infusions if tolerated.
Dose adjustments or discontinuation may be required based on the severity of adverse reactions such as ILD/pneumonitis, ocular events, or stomatitis.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
